Cellular Biomedicine Group Inc. , a biomedicine company engaged in the development of cellular therapies for degenerative and cancerous diseases, today announced its acquisition of Chinese PLA General Hospital's Chimeric Antigen Receptor T cell therapy, its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor's Immuno-Oncology patents , and Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge. "This CAR-T cell technology acquisition further accelerates CBMG's growth in the Immuno-Oncology segment.
http://ift.tt/1zONGnI
http://ift.tt/1zONGnI
No comments:
Post a Comment